Clinical Trials Logo

S-1 clinical trials

View clinical trials related to S-1.

Filter by:
  • None
  • Page 1

NCT ID: NCT05218148 Not yet recruiting - Immunotherapy Clinical Trials

SOX Combined With Sintilimab and Trastuzumab Versus SOX Regimen in the Perioperative Treatment of HER2-positive Locally Advanced Gastric Adenocarcinoma

Start date: April 1, 2022
Phase: Phase 2
Study type: Interventional

The SOX regimen has became the standard perioperative chemotherapy for locally advanced gastric cancer; The immune checkpoint inhibitors have become a standard treatment for advanced or metastatic gastric cancer;For HER2-positive locally advanced gastric cancer, some phase II studies have shown that chemotherapy combined with trastuzumab can further improve the pathological remission rate;This prospective phase II clinical trial was designed, using SOX combined with sintilimab and trastuzumab to treat HER2 positive locally advanced gastric or gastroesophageal junction adenocarcinoma patients.

NCT ID: NCT03589950 Not yet recruiting - Lung Neoplasms Clinical Trials

Anlotinib Plus Chemotherapy for Patients With Advanced Non-small Cell Lung Cancer

Start date: August 1, 2018
Phase: Phase 2
Study type: Interventional

Anlotibib (AL3818) is a kind of innovative medicines approved by State Food and Drug Administration(SFDA:2011L00661) which was researched by Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd. Anlotinib is a kinase inhibitor of receptor tyrosine with multi-targets, especially for VEGFR2、VEGFR3、PDGFRβ and c-Kit. It has the obvious resistance to new angiogenesis. The trial is to explore Anlotinib for the effectiveness and safety of advanced non-small cell lung cancer who failed first lines of chemotherapy

NCT ID: NCT02716688 Withdrawn - Esophageal Cancer Clinical Trials

S-1 and Radiotherapy for Elderly Esophageal Cancer Patients

Start date: January 2016
Phase: Phase 2
Study type: Interventional

To investigate the efficacy and toxicity of S-1 with concurrent radiotherapy in older patients with esophageal cancer.

NCT ID: NCT00961077 Active, not recruiting - Gastric Cancer Clinical Trials

Attenuated SOX as First-line Treatment in Elderly Patients With Relapsed or Metastatic Gastric Cancer

Start date: August 2009
Phase: Phase 2
Study type: Interventional

Stomach cancer is the most common malignant disease and the second most common cause of cancer-related deaths in the Korea. The elderly are primarily affected by the disease with most gastric cancer-related deaths occuring in patients aged 65 years or older. Systemic chemotherapy improves the quantity and quality of life in patients with gastric cancer when compared with best supportive care. However, elderly cancer patients often present with concomitant co-morbidities and age-associated physiologic problems that make the selection of optimal treatment difficult. There is also uncertainty about the use of systemic palliative chemotherapy in elderly patients because of under representation of this age group in clinical trials. Therefore, this phase II trial was planned to investigate efficacy and toxicities of combination chemotherapy with attenuated dose of S-1 and oxaliplatin (attenuated SOX)in patients with elderly AGC